|DEFC14A||definitive proxy statement||Apr 21, 2016||432.6 KB|
|PRER14A||preliminary proxy statement||Apr 13, 2016||433.6 KB|
|PREC14A||preliminary proxy statement||Apr 1, 2016||434.5 KB|
|PRE 14A||preliminary proxy statement||Mar 31, 2016||433.4 KB|
|4||jacobs, cindy||Mar 16, 2016||158.3 KB|
|4||bencich, john||Mar 16, 2016||155.9 KB|
|4||cormack, scott daniel||Mar 16, 2016||170.1 KB|
|10-K||annual report||Mar 9, 2016||767.0 KB|
|8-K||current report||Mar 9, 2016||225.5 KB|
|8-K||current report||Feb 26, 2016||107.3 KB|
|SC 13G/A||amended statement of beneficial ownership||Feb 16, 2016||154.2 KB|
|SC 13G/A||amended statement of beneficial ownership||Feb 16, 2016||164.1 KB|
|8-K||current report||Feb 4, 2016||145.3 KB|
|8-K||current report||Jan 20, 2016||119.3 KB|
|8-K||current report||Jan 7, 2016||107.1 KB|
|8-K||current report||Dec 1, 2015||144.6 KB|
|CT ORDER||confidential treatment order||Nov 19, 2015||8.9 KB|
|10-Q||quarterly report||Nov 12, 2015||436.7 KB|
|8-K||current report||Nov 12, 2015||230.3 KB|
|4||clendeninn, neil james||Oct 30, 2015||152.3 KB|
- Corporate Governance
- Management & Board
- Stock Information
- SEC Filings
- Quarterly Results
- Analyst Coverage
- Webcasts & Presentations
- Scientific Publications & Presentations
- Frequently Asked Questions
© 2004-2016 OncoGenex Pharmaceuticals Inc. All rights reserved.
OncoGenex product candidates are investigational drugs for use only in approved clinical trials.
OncoGenex Pharmaceuticals is a drug discovery and development company uniquely focused on the challenge of cancer treatment resistance.
OncoGenex is uniquely focused on the challenge of cancer treatment resistance. We currently have several on-going clinical trials that may be of interest to you.
OncoGenex focuses on diverse molecular entities that target mechanisms of resistance and that have the potential to re-define treatment paradigms in a variety of cancers.
OncoGenex develops novel compounds designed to meet the persistent challenge of treatment resistance across a variety of cancers.